Search results
Results from the WOW.Com Content Network
The second-line drugs (WHO groups 2, 3, and 4) are only used to treat disease that is resistant to first line therapy (i.e., for extensively drug-resistant tuberculosis (XDR-TB) or multidrug-resistant tuberculosis (MDR-TB)).
The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for tuberculosis. [8 ...
[3] [4] [5] Those at high risk include household, workplace, and social contacts of people with active TB. [4] Treatment requires the use of multiple antibiotics over a long period of time. [1] Antibiotic resistance is a growing problem, with increasing rates of multiple drug-resistant tuberculosis (MDR-TB). [1]
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB .
Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB). Almost one in four people in the world is infected with TB bacteria. [1]
Extensively drug resistant tuberculosis is tuberculosis that is resistant to isoniazid and rifampicin, any fluoroquinolone, and any of the three second line injectable TB drugs (amikacin, capreomycin, and kanamycin). [1] TDR-TB has been identified in three countries; India, Iran, and Italy. The term was first presented in 2006, in which it ...
Pages in category "Anti-tuberculosis drugs" The following 31 pages are in this category, out of 31 total. This list may not reflect recent changes. A. Amikacin; B.
It is in the nitroimidazole class of medications. [5] Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea. [6] It is on the World Health Organization's List of Essential Medicines. [7] As of 2016 the Stop TB Partnership had an agreement to get the medication for US$1,700 per six month for use in more than 100 ...